Elicio Therapeutics completes enrollment of 135 patients in Phase 2 AMPLIFY-7P study for ELI-002

Elicio Therapeutics, Inc.

Phase 2 study ELI-002 7P enrolled 135 mKRAS-driven PDAC patients post-surgery, randomized 2:1 vs observation.
Interim analysis of disease-free survival (DFS) expected in H1 2025, with possible final analysis in H2 2025.
Enrollment pace exceeded expectations; patients eligible cross-over to ELI-002 upon progression.
Primary endpoint is DFS; key secondary endpoints include overall survival and vaccine immunogenicity.
Previous Phase 1a data showed favorable safety and T-cell responses; SITC 2024 data presented.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.